All stock lists
Alcon Inc. (New York Stock Exchange:ALC)
CH · Delayed Price · Currency is USD
Also listed: 0A0D.L, 0A0D.IL, ALC.SWHealthcare · Medical - Specialties
75.06-0.08 (-0.11%)
Market cap
$36.3B
Insider Score
Health Score
Analyst consensus
Listed since
Apr 9, 2019
Website
Insider Score
––Not scored
ALC Insider Score
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
Financial Health Score
Strong
From ALC’s reported statements · Q2 2026 (trailing 12 months)
Profitability13 / 20
Profitable, but on a thin margin.
- Revenue
- $10.81B
- Net income
- $639.3M
- Net margin
- 5.9%
Leverage13 / 20
A manageable debt load.
- Total debt
- $5.30B
- Cash
- $1.35B
- Net debt / EBITDA
- 1.42x
Liquidity20 / 20
Comfortably covers what is due within a year.
- Current assets
- $6.62B
- Current liabilities
- $3.17B
- Current ratio
- 2.09
Cash generation20 / 20
The business funds itself from operations.
- Operating cash flow
- $2.28B
- Free cash flow
- $1.68B
- FCF margin
- 15.6%
Dilution & runway20 / 20
Not funding itself by issuing shares.
- Shares outstanding
- 486.7M
- Share growth (1y)
- -1.7%
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
ALC Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | 2.82 B | 2.65 B | 2.72 B | 2.61 B | 2.60 B | 2.47 B |
| Revenue Growth (YoY) | 8.74 % | 7.30 % | 8.63 % | 6.52 % | 4.01 % | 0.57 % |
| Cost of Revenue | 1.15 B | 1.16 B | 1.25 B | 1.16 B | 1.21 B | 1.09 B |
| Gross Profit | 1.68 B | 1.50 B | 1.47 B | 1.46 B | 1.39 B | 1.38 B |
| SG&A Expense | 964.00 M | 844.27 M | 901.00 M | 865.00 M | 870.00 M | 813.00 M |
| R&D Expense | 663.00 M | 240.24 M | 273.00 M | 250.00 M | 245.00 M | 222.00 M |
| Operating Expenses | 1.66 B | 1.08 B | 1.16 B | 1.13 B | 1.14 B | 915.00 M |
| Operating Income | 11.00 M | 410.86 M | 313.00 M | 332.00 M | 247.00 M | 468.00 M |
| Pretax Income | -46.00 M | 235.34 M | 264.00 M | 283.00 M | 199.00 M | 414.00 M |
| Tax Provision | -46.00 M | 50.01 M | 47.00 M | 46.00 M | 23.00 M | 64.00 M |
| Net Income | 0.00 | 185.33 M | 217.00 M | 237.00 M | 176.00 M | 350.00 M |
| EPS (Basic) | 0.00 | 0.38 | 0.44 | 0.48 | 0.36 | 0.71 |
| EPS (Diluted) | 0.00 | 0.38 | 0.44 | 0.48 | 0.35 | 0.70 |
| Shares Outstanding | 486.70 M | 487.20 M | 489.30 M | 493.20 M | 495.20 M | 495.10 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.